PT2991671T - Dosagem oral de compostos de glp-1 - Google Patents

Dosagem oral de compostos de glp-1

Info

Publication number
PT2991671T
PT2991671T PT14721834T PT14721834T PT2991671T PT 2991671 T PT2991671 T PT 2991671T PT 14721834 T PT14721834 T PT 14721834T PT 14721834 T PT14721834 T PT 14721834T PT 2991671 T PT2991671 T PT 2991671T
Authority
PT
Portugal
Prior art keywords
glp
compounds
oral dosing
dosing
oral
Prior art date
Application number
PT14721834T
Other languages
English (en)
Inventor
Seier Nielsen Flemming
Sauerberg Per
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190381&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2991671(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PT2991671T publication Critical patent/PT2991671T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT14721834T 2013-05-02 2014-05-02 Dosagem oral de compostos de glp-1 PT2991671T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13166205 2013-05-02

Publications (1)

Publication Number Publication Date
PT2991671T true PT2991671T (pt) 2018-11-05

Family

ID=48190381

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14721834T PT2991671T (pt) 2013-05-02 2014-05-02 Dosagem oral de compostos de glp-1

Country Status (24)

Country Link
US (3) US20160067184A1 (pt)
EP (2) EP3485900A1 (pt)
JP (2) JP6672140B2 (pt)
KR (3) KR20180115814A (pt)
AU (1) AU2014261336B2 (pt)
BR (1) BR112015026325A2 (pt)
CA (1) CA2910903A1 (pt)
CY (1) CY1120730T1 (pt)
DK (1) DK2991671T3 (pt)
ES (1) ES2688462T3 (pt)
HR (1) HRP20181393T1 (pt)
HU (1) HUE040609T2 (pt)
IL (1) IL241813A (pt)
LT (1) LT2991671T (pt)
MX (3) MX369259B (pt)
MY (1) MY172578A (pt)
PL (1) PL2991671T3 (pt)
PT (1) PT2991671T (pt)
RS (1) RS58039B1 (pt)
RU (1) RU2671406C2 (pt)
SA (1) SA515370075B1 (pt)
SI (1) SI2991671T1 (pt)
WO (1) WO2014177683A1 (pt)
ZA (2) ZA201507096B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
PT2696687T (pt) 2011-04-12 2017-02-02 Novo Nordisk As Derivados de glp-1 duplamente acilados
ES2690553T3 (es) 2012-03-22 2018-11-21 Novo Nordisk A/S Composiciones de péptidos GLP-1 y preparación de estas
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
MX369259B (es) 2013-05-02 2019-11-04 Novo Nordisk As Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
KR102294577B1 (ko) 2015-01-12 2021-08-26 엔터리스 바이오파마, 인크. 고체 경구 제형
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US11196462B2 (en) 2016-02-22 2021-12-07 Qualcomm Incorporated Multi-layer beamforming in millimeter-wave multiple-input/multiple-output systems
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
SG11202002841PA (en) * 2017-10-12 2020-04-29 Novo Nordisk As Semaglutide in medical therapy
MX2020004497A (es) * 2017-10-31 2020-08-13 Medimmune Ltd Administracion oral de analogos del peptido glp-1.
ES2960687T3 (es) 2018-02-02 2024-03-06 Novo Nordisk As Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3107345A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
US11471512B2 (en) * 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
WO2021089752A1 (en) 2019-11-07 2021-05-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
TW202140063A (zh) 2020-02-18 2021-11-01 丹麥商諾佛 儂迪克股份有限公司 醫藥配方
EP4142695A1 (en) 2020-04-29 2023-03-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
JP2023534130A (ja) * 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス Ｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
BR112023000270A2 (pt) 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
EP4360645A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition containing glp-1 compound
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
KR20240036563A (ko) 2021-07-15 2024-03-20 노보 노르디스크 에이/에스 N-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 정제
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
KR20230132256A (ko) 2022-03-08 2023-09-15 이정열 오징어 조획장치
KR20230147981A (ko) 2022-04-15 2023-10-24 이정열 어류 탈취기
KR20230167546A (ko) 2022-06-02 2023-12-11 이정열 어류 탈취기
KR20240018118A (ko) 2022-08-02 2024-02-13 이정열 어류 탈취기
WO2024040356A1 (en) * 2022-08-25 2024-02-29 The University Of British Columbia Mucoadhesive pharmaceutical dosage form for unidirectional release of peptide therapeutic particles
KR20240055265A (ko) 2022-10-20 2024-04-29 이정열 어류 탈취기
WO2024110614A1 (en) * 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU775063C (en) 1999-04-30 2005-05-12 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
CN1501809B (zh) * 2000-12-13 2012-10-10 伊莱利利公司 应用胰高血糖素样促胰岛肽的长期治疗方案
PL209734B1 (pl) 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
WO2005014049A2 (en) 2003-08-08 2005-02-17 Novo Nordisk A/S Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
PL2347762T3 (pl) 2005-08-19 2019-09-30 Amylin Pharmaceuticals, Llc Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
WO2007061434A2 (en) 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
JP2009520693A (ja) 2005-12-08 2009-05-28 エムディーアールエヌエー，インコーポレイテッド 安定化されたエキセンディン製剤の粘膜送達
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
JP5021033B2 (ja) 2006-09-07 2012-09-05 エフ．ホフマン−ラ ロシュ アーゲー Ｓｎａｃ（サルカプロザートナトリウム）の製造法
CL2007002634A1 (es) * 2006-09-13 2008-05-16 Smithkline Beecham Corp Uso de una composicion que comprende al menos un polipeptido que tiene actividad de peptido-1 semejante a glucagon (glp-1) como agente hipoglucemiante de larga duracion.
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
RU2494755C2 (ru) 2008-08-18 2013-10-10 Интера Био Лтд. Способы и композиции для перорального введения белков
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN102869676A (zh) * 2010-04-30 2013-01-09 株式会社三和化学研究所 用于提高生理活性物质等的生物体内稳定性的肽和提高了生物体内稳定性的生理活性物质
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
PT2696687T (pt) * 2011-04-12 2017-02-02 Novo Nordisk As Derivados de glp-1 duplamente acilados
JP6006309B2 (ja) * 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニーＡｍｙｌｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｌｌｃ 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2690553T3 (es) * 2012-03-22 2018-11-21 Novo Nordisk A/S Composiciones de péptidos GLP-1 y preparación de estas
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
MX369259B (es) 2013-05-02 2019-11-04 Novo Nordisk As Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).

Also Published As

Publication number Publication date
US20190216739A1 (en) 2019-07-18
KR20210086717A (ko) 2021-07-08
ES2688462T3 (es) 2018-11-02
ZA201507096B (en) 2020-01-29
US10278923B2 (en) 2019-05-07
PL2991671T3 (pl) 2019-01-31
MY172578A (en) 2019-12-03
MX369259B (es) 2019-11-04
JP2016519128A (ja) 2016-06-30
DK2991671T3 (en) 2018-10-08
US20160067184A1 (en) 2016-03-10
US20170312225A1 (en) 2017-11-02
WO2014177683A1 (en) 2014-11-06
RU2671406C2 (ru) 2018-10-31
KR20180115814A (ko) 2018-10-23
KR102272671B1 (ko) 2021-07-06
AU2014261336B2 (en) 2019-02-28
SA515370075B1 (ar) 2017-08-27
RS58039B1 (sr) 2019-02-28
SI2991671T1 (sl) 2018-10-30
JP2020073533A (ja) 2020-05-14
HUE040609T2 (hu) 2019-03-28
HRP20181393T1 (hr) 2018-11-02
MX2015015009A (es) 2016-03-09
CA2910903A1 (en) 2014-11-06
BR112015026325A2 (pt) 2017-07-25
AU2014261336A1 (en) 2015-10-08
LT2991671T (lt) 2018-09-25
MX2019013123A (es) 2019-12-05
EP2991671B1 (en) 2018-08-15
IL241813A (en) 2017-12-31
RU2015147876A (ru) 2017-06-06
KR20160002945A (ko) 2016-01-08
CY1120730T1 (el) 2019-12-11
EP2991671A1 (en) 2016-03-09
ZA201806791B (en) 2019-06-26
MX2018012166A (es) 2020-09-02
JP6672140B2 (ja) 2020-03-25
EP3485900A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
ZA201806791B (en) Oral dosing of glp-1 compounds
GB201322602D0 (en) Pharmaceutical compounds
HRP20181607T1 (hr) Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke
GB201306610D0 (en) Pharmaceutical compounds
IL244380A0 (en) Pharmaceutical compounds
GB201312386D0 (en) Pharmaceutical compounds
PT2948129T (pt) Compostos terapêuticos
GB201305103D0 (en) An oral dosage form
GB201413253D0 (en) Solid dosage form
GB201314286D0 (en) Therapeutic Compounds
GB201312499D0 (en) Therapeutic compounds
GB2520315B (en) Oral Syringes
GB201407847D0 (en) Composition for the oral delivery of compounds
GB201320905D0 (en) Therapeutic compounds
GB201314397D0 (en) Therapeutic Compounds
GB201311169D0 (en) Therapeutic compounds
GB201317166D0 (en) Pharmaceutical compounds
GB201316780D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds
GB201308782D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308780D0 (en) Pharmaceutical compounds